Meet 15 Startups in ISB DLabs’ I-HEAL Fourth Cohort Tackling Critical Healthcare Gaps

Why It Matters

By linking early‑stage innovators with hospital networks and capital, I-HEAL accelerates scalable solutions that can improve outcomes for 63 million hearing‑impaired Indians, boost IVF success rates and curb antibiotic misuse, reshaping the Indian health ecosystem.

Key Takeaways

• I-HEAL’s fourth cohort backs 15 health‑tech startups in diagnostics, neuro‑rehab, women’s health
• Program provides clinical validation, regulatory help, and mentorship via ISB and CitiusTech
• Startups include BabyCue diarrhoea test, Garbha.ai IVF platform, Ksham bone‑conduction hearing glasses
• Funding secured includes Ultramotiv’s Rs 76 lakh (~$91 k) seed capital and multiple grants
• Cohort tackles gaps affecting 63 million hearing‑impaired, IVF success rates, and antibiotic overuse

Pulse Analysis

India’s healthcare system faces chronic shortages—from 63 million people with untreated hearing loss to stagnant IVF success rates and rampant antibiotic overuse in children. Accelerators like I-HEAL, run by ISB DLabs and backed by CitiusTech, are designed to bridge these gaps by fast‑tracking startups that have already cleared early technical hurdles. By offering structured clinical partnerships, regulatory navigation and investor‑readiness coaching, the program ensures that innovations move beyond lab prototypes to real‑world deployment in hospitals and community settings.

The fourth I-HEAL cohort showcases the breadth of emerging solutions. BabyCue’s rapid colourimetric kit differentiates bacterial from viral diarrhoea, directly targeting antibiotic resistance. Garbha.ai leverages multimodal AI to improve embryo grading, aiming to lift IVF success rates above the long‑standing 30‑35 % ceiling. Ksham Innovation’s bone‑conduction Able Glasses provide a low‑cost hearing aid alternative for the majority of India’s hearing‑impaired population. Other ventures, such as Ultramotiv’s modular robotic rehab arm and Sensio’s ECG‑enabled smart ring, illustrate how hardware‑enabled SaaS models are gaining traction with both clinicians and consumers.

For investors and policymakers, the cohort signals a maturing health‑tech landscape where clinical validation and scalability are becoming core criteria. The infusion of seed capital—evident in Ultramotiv’s roughly $91 k funding—and multiple grant awards highlights growing confidence in these ventures. As these startups scale across ten‑city rollouts and secure hospital partnerships, they could collectively reshape care delivery, lower costs and improve outcomes for millions, making India a fertile ground for the next wave of global health innovation.